Sushmita Panda (@SushmitaPanda) header
Sushmita Panda (@SushmitaPanda) profile picture

Global Pharma Reporter @PharmaScrip, @Norstellaco | Alum: @acjindia | tip/lead: [email protected] | 📩 Signal: Sushmita.33

Delhi, India
Joined August 2011
Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)Photo by Sushmita Panda (@SushmitaPanda)
Super excited to share that I received an Honorary Mention in the #ProjectSirenAwards2025 for my story "FE Mental Health Series | Every 40 seconds, someone dies by suicide – Can we prevent the next?" Grateful for the recognition!
1/3 🔶 Our next honorary mention goes to @SushmitaPanda for her piece in the E Mental Health series, ‘Every 40 seconds, someone dies by suicide—Can we prevent the next?’ Her story frames suicide as a preventable crisis..
1
1
5
2,539
Sushmita Panda retweeted
A healthcare system built on incomplete data leaves lasting blind spots. Guest contributor Jessica Federer explores the implications of a striking fact: women weren't required in US studies until 1993. Read The Long View here capsul.news/the-long-view-of…
1
1
1
15
India wants to move beyond its identity as the “pharmacy of the world” and become a global hub for pharma innovation. In an interview with @PharmaScrip , OPPI DG Anil Matai discusses the R&D investment, regulatory predictability and policy changes needed to make that transition. insights.citeline.com/scrip/…
1
58
India supplies about 20% of global generics, but its presence in early-stage drug development and newer modalities remains limited. At the #OPPIsummit, industry leaders called for a bigger role in global clinical research, even as an OPPI-EY report highlighted persistent gaps in home-grown innovation and out-licensing. Latest for @PharmaScrip insights.citeline.com/scrip/…
14
A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced. wapo.st/4t6oIRy
119
1,599
316
6,186
838,312
Sushmita Panda retweeted
Rasonque booked $197.6m in roughly five weeks to Sept. 30 after its Aug. 26 FDA approval, the best launch-quarter sales for an oncology drug ever. Revolution’s CEO is still tempering expectations. Why? Therapeutic Thursday. Read it here... capsul.news/therapeutic-thur…
1
1
1
31
Sushmita Panda retweeted
After taking over epithelial tumors, ADCs are coming for treating sarcomas! Encouraging phase 1 data with the uPARAP-directed ADC ADCE-D01, with 30% ORR across multiple types of sarcoma. Key tox: neutropenia (requiring growth factors), nausea, IRR. #ENA26
9
2
85
7,702
Sushmita Panda retweeted
So proud to see my colleague Ritika Chopra in this "TIME 100 India" list. The citation covers the spectacular range of her work — education to politics — and flags all the attributes that make it stand apart: hard work, rigour, nurturing sources, all off camera. This is an inspiration for all our formidable young talent in the Express newsroom — and beyond. time.com/collection/time100-…
53
156
18
835
51,950
Sushmita Panda retweeted
In journalism, writer's block often just means you haven't done enough reporting. Conversely, if you can close your eyes & imagine the layout of the piece with some clarity, then it's probably time to start writing
8
86
10
747
42,075
Sushmita Panda retweeted
Story exposing reality of India’s ‘progressive’ abortion law👇🏽 A comment on majority of awful ob-gyn doctors/nurses (mostly women) who don’t seem to have basic training in empathetic, ethical healthcare In any civilised country they would be stripped of licence and penalised
India’s abortion laws promise women the right to make decisions about their own bodies. But inside hospitals, that choice often comes at the cost of humiliation, coercion, delayed treatment, and medical abuse. thenewsminute.com/news/the-c…
1
23
2
70
5,359
Sushmita Panda retweeted
Are you thinking of leaving Delhi-NCR because of the air pollution? Six professionals and founders already did. Here's what they gained, and what it cost them. In today's @IndianExpress 🧵
12
71
10
194
20,893
the @FDA has declined to approve ivonescimab in advanced NSCLC because of lack of OS benefit*. Interesting how the 'culture' of different diseases affects norms and standards for regulatory approval. The landscape of advanced breast cancer treatment would look very different and have different kinetics if OS was required for approval. *this instance may also be affected by the fully ex-US nature of the particular trial smmttx.com/news/press-releas…
10
23
3
98
23,049
Sushmita Panda retweeted
JUST IN: the @FDA has declined to approve PD1/VEGF bispecific ivonescimab in advanced NSCLC with EGFRm, because of lack of OS benefit (via @Reuters) — Having seen approval in several cancers based on PFS, this is somewhat a puzzling rejection. reuters.com/legal/litigation…
8
26
3
105
20,661
FDA is shelving the Commissioner's National Priority Voucher program, according to a Reuters report.
22
13
13
149
52,221
Sushmita Panda retweeted
being a journalist:
1
147
2
906
31,007
Sushmita Panda retweeted
Biopharma CEO "This presentation contains forward-looking statements, as a result of risks and uncertainties..." AI/Tech CEO "We will cure all diseases in less than 10 years"
13
61
5
647
23,502
Sushmita Panda retweeted
Good that you are finally reading a book! Can you please refrain from tweeting about it every 5 mins?
30
67
11
470
19,976